Not recruiting
Epstein-Barr virus associated lymphoma
Not recruitingStudy on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas
Registered drugNo placebo
Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas
Registered drugNo placebo
- Disease:Epstein-Barr virus associated lymphoma
- Substances:Ganciclovir SodiumNanatinostat+1
Countries:
France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Ganciclovir Sodium



